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Abstract
Background: Cystic ﬁbrosis (CF) is the most common inherited disease in Caucasians, affecting around 10,000 individuals in the UK today.
Prognosis has improved considerably over recent decades with ongoing improvements in treatment and care. Providing up-to-date survival
predictions is important for patients, clinicians and health services planning.
Methods: Flexible parametric survival modelling of UK CF Registry data from 2011 to 2015, capturing 602 deaths in 10,428 individuals. Survival
curves were estimated from birth; conditional on reaching older ages; and projected under different assumptions concerning future mortality trends,
using baseline characteristics of sex, CFTR genotype (zero, one, two copies of F508del) and age at diagnosis.
Findings:Male sex was associated with better survival, as was older age at diagnosis, but only in F508del non-homozygotes. Survival did not differ by
genotype among individuals diagnosed at birth. Median survival ages at birth in F508del homozygotes were 46 years (males) and 41 years (females),
and similar in non-homozygotes diagnosed at birth. F508del heterozygotes diagnosed aged 5 had median survival ages of 57 (males) and 51 (females).
Conditional on survival to 30, median survival age rises to 52 (males) and 49 (females) in homozygotes. Mortality rates decreased annually by 2%
during 2006–2015. Future improvements at this rate suggest median survival ages for F508del homozygous babies of 65 (males) and 56 (females).
Interpretation: Over half of babies born today, and of individuals aged 30 and above today, can expect to survive into at least their ﬁfth decade.
Research in context
Evidence before this study
We searched PubMed with terms “(cystic ﬁbrosis survival) and (projection OR model OR registry OR United Kingdom OR UK)” to identify
relevant studies on survival estimates for individuals with cystic ﬁbrosis (CF). We also considered the most recent annual report from the UK Cystic
Fibrosis Registry (Cystic Fibrosis Trust, 2016), a review by Buzzetti and colleagues (2009), the chapter on Epidemiology of Cystic Fibrosis by
MacNeill (2016), the study of MacKenzie and colleagues (2014), and references therein. There have been many studies of factors associated with
survival in CF; most have focused on identifying risk factors, and only a few have presented estimated survival curves, which are the focus of this work.
The most recent study of survival in the UK is by Dodge and colleagues (2007), who used data obtained from CF clinics and the national death register,
and gave an estimate of survival for babies born in 2003. We found no previous studies that have obtained detailed information on survival using UK
Cystic Fibrosis Registry data. Jackson and colleagues obtained survival estimates for the US and Ireland using registry data (Jackson et al., 2011).
MacKenzie and colleagues used US Cystic Fibrosis Foundation Patient Registry data from 2000 to 2010 to project survival for children born and
diagnosed with CF in 2010, accounting for sex, genotype and age at diagnosis (MacKenzie et al., 2014). Previous studies on estimated survival in CF
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have become out of date or have not accounted for the full range of patient characteristics available at birth. Few have presented conditional survival
estimates (Dodge et al., 2007).
Added value of this study
This is the ﬁrst study to yield detailed survival statistics using the UK Cystic Fibrosis Registry, which is one of the largest national CF registries
outside of the US and has almost complete coverage of the UK CF population. The primary goal was to leverage the long-term follow-up of the
nearly complete UK CF population available in the Registry for the purposes of producing accurate, precise predictions in the modern era of CF
care. Estimates are presented from birth and conditional on survival to older ages. These are the ﬁrst conditional estimates in CF to also account for
genotype, sex and age at diagnosis, which were each included in the modelling using a ﬂexible approach. Projections are also provided under
different scenarios based on downward trends in mortality rates. Our use of ﬂexible parametric survival models is novel in this ﬁeld, and our
approach could be used to provide modern survival statistics for other chronic diseases and disorders.
Implications of all the available evidence
Our estimates of future survival in CF under a range of different scenarios are based on data on nearly all individuals living with the disease in
the UK in recent times, reﬂective of a modern era of care, and are most appropriate for the families of babies being born in the present day with CF.
Conditional estimates inform patients who have already reached an older age, and their clinicians. Over half of babies born today, and of
individuals aged 30 years and above alive today, can expect to survive into their ﬁfth decade. Insights based on our survival projections can be
used to inform future needs in CF health care provision.
© 2017 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Cystic fibrosis (CF) is the most common inherited disease in
Caucasian populations, affecting around 10,000 individuals in
the UK today [1]. Most patients with CF die prematurely from
respiratory failure and require support from healthcare services
from diagnosis onwards [2]. Survival of people with CF has
improved considerably over recent decades due to improve-
ments in treatment and care and the estimated median survival
age is one of the headline results reported in national registry
reports. Information on predicted survival based on up-to-date
data is important for people with CF, their families and the
health professionals who care for them [3–5].
Survival estimates for people with CF are typically limited to
median survival age at birth, stratified by sex, for instance,
48 years for males and 43 years for females in the UK [1].
However, these estimates are of limited use to patients who have
already survived to a given age, and they do not take into account
the full range of patient characteristics available at birth.
Furthermore, current survival estimates in CF do not account
for ongoing improvements in treatment and care. Mortality rates
continue to decrease over time and this is anticipated to continue
in the future, not least due to new targeted therapies [6,7].
We therefore use novel survival analysis approaches to make
projections of survival for babies born with CF in the present day,
and for people who have survived to particular ages. We do this
while taking into account baseline patient characteristics, and
decreasing mortality trends over time, making use of the long
term follow-up in the UK Cystic Fibrosis Registry, which is one
of the largest national CF registries outside of the US and has
almost complete coverage of the UK CF population [8]. Our aim
is to provide more individually relevant information on survival
for people with CF in the UK and projections that are relevant for
planning future health care resource needs. Summary survival
statistics are accompanied by clear interpretations and estimates
of their uncertainty.
2. Methods
2.1. Study design and data source
This cohort study used longitudinal data from the UK CF
Registry collected between 2006 and 2015. The UK CF Registry
is a secure centralised database, sponsored and managed by the
Cystic Fibrosis Trust, which records data on the demographics,
health and treatment of almost all people with CF in the UK [8].
The analysis progressed in two parts. For the main analysis we
used data on all individuals followed in the UK CF Registry
during the 5-year period from 1st January 2011 to 31st December
2015 to estimate survival based on the latest age-specific mortality
rates. Covariates in this analysis were sex, CFTR genotype (coded
as the number of F508del alleles: two (homozygous), one
(heterozygous), zero copies), and age at diagnosis. For our second
analysis, in order take into account secular trends in survival, we
used 10 years of longitudinal follow-up data, from 1st January
2006 to 31st December 2015, in order to obtain a more precise
estimate of changes in hazards with calendar time.
Individuals who did not die during the analysis period were
right-censored as follows. For those observed in the registry in
2015, we used their age at 31st December 2015 as the age of
censoring; for those who were lost to follow-up, we used their age
at the 31st December on their last year of providing data to the
Registry plus two years. Individuals who were not seen for a
period in the middle of the study period and then reappeared were
considered to be observed for the full intervening time in the
analysis. Ages were left-truncated at the later of: age at 1st
January 2011 (main analysis) or age at 1st January 2006 (second
analysis), age of diagnosis, or age at first joining the Registry.
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Ages at death or censoring and at left-truncation time were
calculated using differences between relevant dates. Dates of
birth and death were available in “month-year” format and the
day was taken as the 15th of the month.
2.2. Statistical analysis
First we summarized the study population by sex, F508del
status and age at diagnosis. We also summarized the survival data
by number of deaths, births, new diagnoses and losses-to-
follow-up, and person years at risk.
For all survival analyses, age was used as the time scale; [9]
we used the period approach to yield up-to-date projections of
long-term survival [10,11]. We used flexible parametric survival
models adjusting for baseline covariates [12]. Age at diagnosis
was modelled using a restricted cubic spline. Flexible parametric
survival models have the advantage of providing smooth flexible
survivor curves. They use restricted cubic splines to model the
log baseline cumulative hazard to achieve a good fit to the data,
which may not be achievable using the standard set of parametric
survival models (e.g. Weibull, log-logistic). The methodology
and model building strategy are described in the Supplementary
Materials (S1, S2). Our final model was used to obtain survival
curves by sex, F508del status and age at diagnosis. Conditional
survivor curves were also obtained (see Supplementary Materials
S2), conditional on survival to ages 20, 30, 40, 50. Model fit was
assessed by comparisons with Kaplan-Meier curves (Supple-
mentary Materials S5) [13].
Estimates from the main analysis are based on the assumption
that current mortality rates will continue to apply in the future,
which does not account for potential future decreases in mortality
rates due to improved treatment and care. Our final model was
extended to enable projection of future survivor curves under
different assumptions about how mortality rates may improve
(Supplementary Materials S3). We provide results based on two
projections: (1) improvements in mortality rates will continue at
the same rate as estimated over the ten years 2006–2015 (2%
reduction in mortality rates per year); (2) improvements in
mortality rates will continue at half that rate (1%). The annual
change in age-specific mortality rates was estimated by fitting our
final selected model with an additional linear term in calendar
year. For this we used data from 2006 to 2015, with the aim of
obtaining a more precise estimate of changes in hazards with
calendar time. The estimated hazard ratio for each calendar year
was used to modify the flexible parametric survivor curves under
the above two scenarios for future mortality rates. These are the
same scenarios as were considered byMacKenzie and colleagues
[14].
3. Results
3.1. Population characteristics
10,428 individuals (95.3%) had data on all covariates and
were included in the analysis. We excluded 414 individuals
(3.8%) with missing F508del genotype status and 129 individuals
(1.2%) with missing age at diagnosis. The median age among
those alive at the start of 2011 was 18.1 (IQR: (9.3–27.6), range:
(0, 81.4)). During the 5-year period 2011–2015, there were 602
deaths, 1215 births, and 1569 new diagnoses (including newborn
diagnoses). Only 142 individuals (1.4%) were defined as being
lost to follow-up during the 5-year period.
Table 1 shows the baseline characteristics of the study sample
used for the main analysis (2011–2015). There were slightly fewer
females than males (47.1% versus 52.9%). Half of individuals
(51.0%) were F508del homozygous and 39.4% were F508del
heterozygous. The majority (67.2%) were diagnosed under age
one. Median age at diagnosis was 0.2 years, with range 0 to
79 years. See Supplementary Table 1 for summary statistics for
2006–2015.
3.2. Models for survival
The final selected flexible parametric survival model included
sex, F508del status and interactions between age at diagnosis and
being F508del heterogeneous or having no copies of F508del.
Age at diagnosis was not associated with survival in the F508del
homozygous group after accounting for sex. The complete
specification of the model is given in the SupplementaryMaterials
(S4). Associations between covariates and survival are summa-
rized in Fig. 1. Females had a 31% increased hazard (HR 1.31,
95% CI (1.12, 1.54)) independently of genotype and age at
diagnosis. For those diagnosed at age 0 the hazard did not differ
between the three genotype groups (F508del heterozygous: HR
1.03, 95% CI (0.85, 1.26), F508del zero copies: HR 1.13 (0.77,
1.66)), but we decided to retain those terms to illustrate this point
clinically and because their inclusion did not result in substantial
widening of survival curve confidence intervals. In individuals
with zero or one copy of F508del, older age at diagnosis was
associated with a reduced hazard up to around age 15 and then
levelled off. The form of the association was remarkably similar in
the two groups. The final model was found to provide an excellent
fit to the data (Supplementary Fig. 4).
Table 1
Descriptive statistics for included individuals observed in the UK Cystic Fibrosis
Registry between 1st January 2011 and 31st December 2015 (N = 10,428).
N % No. deaths Person years of
follow-up
Sex
Male 5519 52.9 295 24,291.9
Female 4909 47.1 307 21,481.3
F508del status
Homozygous
(2 copies)
5314 51.0 336 23,711.4
Heterozygous
(1 copy)
4107 39.4 214 17,793.5
0 copies 1007 9.7 52 4268.3
Age at diagnosis
Median, IQR 0.2 (0.06, 2.03)
b1 7006 67.2 373 30,529.6
1–4 1792 17.2 129 8363.7
5–9 488 4.7 29 2205.4
10–24 570 5.5 21 2511.0
25+ 572 5.5 50 2163.6
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Results that are ages are rounded to the nearest whole age for
presentation in the text. Fig. 2 shows estimated survivor curves and
summary statistics, focusing on F508del homozygous individuals
(diagnosed at any age) and F508del non-homozygotes diagnosed
at age zero. As we expect based on the hazard ratio results (Fig. 1),
the estimated curves in the three genotype groups are very similar,
while the survival curves for males are consistently higher than for
females. In F508del homozygotes 75% of males are expected to
live beyond age 31 (95% CI 29–33), and 75% of females beyond
age 27 (95% CI 26–29). The median survival ages for males and
females in the F508del homozygous groups are respectively 46
(95% CI 43–48) and 41 (95% CI 38–43), and 25% of males are
expected to live beyond age 60 (95% CI 56–65) and 25% of
females beyond age 54 (95% CI 51–58).
3.3. Conditional survival curves
Fig. 3 shows estimated conditional survivor curves for
F508del homozygotes. In F508del homozygous males, the
median survival age conditional on survival to age 30 is 52
(95% CI 50–55), which is an almost 7-year increase on the
estimated median survival age from birth (46, 95% CI 43–48). In
F508del homozygous females, the median survival age condi-
tional on survival to age 30 is 49 (95% CI 46–51), compared to
the estimated median survival age from birth of 41 (95% CI 38–
43). Conditional survivor curves for individuals with zero or one
copy of F508del and diagnosed at age zero are very similar to
those shown for homozygous individuals and are shown in
Supplementary Fig. 1.
Fig. 3 also illustrates the impact of age at diagnosis on
estimated survival curves in F508del heterozygotes, via estimated
survivor curves for individuals diagnosed at age 5. F508del
heterozygous individuals diagnosed at age 5 have significantly
improved survival compared to those diagnosed at age 0. For
example, the estimated median survival age in males is 45 (95%
CI 41–49) for those diagnosed at age 0 and 57 (95%CI 52–62) for
those diagnosed at age 5. In females the corresponding estimates
are 40 (95% CI 37–43) and 51 (95% CI 47–55). The conditional
survival estimates are also considerably higher in those diagnosed
at an older age, though are accompanied by increasingly wide
confidence intervals due to the relatively little information on
individuals with older age at diagnosis. See Supplementary Figs. 2
and 3 for results for older age at diagnosis and those with zero
copies of F508del.
3.4. Projected survival curves
The estimated HR for a one-year increase in calendar time
during 2006–2011 was 0.98 (95% CI 0.96–1.00), indicating that
mortality rates reduced by 2% each year. This corresponds to a
decrease of 21% (HR 0.79, 95% CI 0.64–0.97) over ten years.
We focus on projections for F508del homozygous individuals,
for whom age at diagnosis was not important. Projections for
individuals with zero or one copy of F508del and diagnosed at
age 0 are very similar under our model (Supplementary Fig. 6).
However, in the light of newborn screening for CF in the UK
since 2007 results for non-homozygotes would be expected to
change because individuals who in the past would have been
diagnosed at an older age would now be diagnosed at birth [15].
We did not consider it appropriate to present projections from
birth in groups who in the past would have been diagnosed at an
older age.
Fig. 4 shows projected survival curves. If recent trends in
decreasing mortality rates continue at the same rate (2% per
year) the median survival age for F508del homozygote children
born today is estimated to be 65 for males (95% CI 56–74) and
56 for females (95% CI 51–61). Compared with estimates from
the main analyses, which assume current mortality rates will
Fig. 1. Final model results: Estimated hazard ratios (HR) and corresponding 95% confidence intervals (CI). The hazard ratios for age at diagnosis are shown
graphically, with the shaded area representing the 95% CIs.
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hold in the future, these results correspond to an increase in
median survival age of 20 years in males and 15 years in
females. Under the conservative projection assuming hazard
rates reduce by 1% per year, median survival is estimated to
increase by eight years in males and six years in females. For
context, these results compare with life expectancy estimates
for the general UK population of 79.1 in males and 82.8 in
females [16].
4. Discussion
We outline a novel approach to estimating survival in people
with CF, using data from the UK CF Registry. We provide
survival curves from birth taking into account sex, genotype and
age at diagnosis, and update these estimates conditional on
survival to later ages. We show that under current mortality rates
and in babies born today with the most common genotype
Fig. 2. Estimated survival curves for F508del homozygous individuals (diagnosed at any age) and for individuals with 0 or 1 copy of F508del diagnosed at age 0. Left
panel: by F508del status within males and females. Right panel: by sex within F508del group. The shaded areas represent the 95% confidence intervals. The table
shows the estimated ages (Est), and 95% confidence intervals (CI), beyond which 75%, 50% and 25% of individuals survive in groups defined by sex and F508del
status.
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(F508del homozygous), half of males are expected to live beyond
age 46 and half of females beyond age 41. If CF mortality rates
continue to decrease by 2% per year this increases to 65 for males
and 56 for females. These up-to-date survival statistics will be
important to inform planning of health care services, given the
evidence for continued improvements in survival in CF over time.
They also inform patients making life and treatment decisions and
clinicians making treatment choices. For individual patients who
Fig. 3. Estimated conditional survival curves for F508del homozygous individuals conditional on survival to ages 20, 30, 40, 50; and for F508del heterozygous
individuals diagnosed at age 5 and conditional on survival to diagnosis and to ages 20, 30, 40, 50. Left panel: males. Right panel: females. The table shows the
estimated ages (Est), and 95% confidence intervals (CI), beyond which 75%, 50% and 25% of individuals survive conditional on survival to a given age in groups
defined by sex and F508del status.
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have already reached a given age, measures of current health
status, for example lung function, are likely to be more important
predictors of survival than baseline characteristics, and providing
such estimates using the longitudinal data available in the
Registry is an area of ongoing work. Our findings should be
interpreted in the light of the uncertainty and assumptions
involved, as highlighted in figures displaying the main results
(Figs. 2–4). We refer to a complementary paper for a detailed
commentary on interpretation of median survival estimates [17].
There is a large literature on survival in CF. [18,19] Previous
studies have presented survival statistics in CF based on national
data though we are the first to provide detailed information on
survival using the UK CF Registry. Dodge et al. [4] assessed CF
survival in the UK during 1947–2003 using data from CF clinics
and the national death register based on both birth cohort and
current life table approaches, the latter being equivalent to the
period approach employed in this study. Similar studies were
performed by the same authors using earlier data [20,21]. Elborn
and colleagues used national mortality data for CF in England and
Wales from 1959 to 1986 to predict survival of individuals born
with CF up to 1990 [3]. MacKenzie and colleagues used US CF
Foundation Patient Registry data from 2000 to 2010 to project
survival for children born and diagnosed with CF in 2010 [14].
They used kernel-smoothed survivor curves obtained by Cox
regression modelling, in contrast to our flexible parametric
survival modelling approach, which arguably provides a more
theoretically sound option for obtaining smooth estimated survival
curves. Jackson and colleagues fitted parametric survival models
based on a Weibull model to US Registry data from the 1980–
1994 birth cohort, taking into account sex and birth cohort [5]. The
parametric models developed on the US population were
extrapolated to infer estimates of longer-term survival and were
also applied to data from the CFRegistry of Ireland.We compared
our flexible models with a Weibull model and found the former to
provide a better fit to the data (Supplementary Fig. 5).
In our study we estimate median survival at birth to be
46 years in males and 41 years in females for babies born with
CF now who are F508del homozygous, based on the conserva-
tive assumption that mortality rates will remain at the current
level. These estimates are a little lower than those reported in
recent UK CF Registry Annual Report [1] (48 for males, 44 for
females), which do not account for genotype or age at diagnosis.
Dodge and colleagues estimated a mean age of survival of 43 in
males and 37 in females for a child born with CF in 2003 [4],
while Elborn and colleagues estimated median survival of age 40
for a child born with CF in 1990 [3]. These estimates did not
account for genotype or age at diagnosis. Given findings
presented in the UK CF annual registry reports that overall
survival is improving over time, and our finding of decreasing
mortality rates over time, it is logical that our up-to-date estimates
for the UK are higher. Jackson and colleagues estimated median
survival of 51 for males and 42 for females among individuals
born during 1985–1994 in the US and who survived to their first
birthday [5]. Corresponding estimates for Ireland were 51 and 39.
Fig. 4. Projected survival curves for F508del homozygous individuals diagnosed at birth.
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Although based on non-UK populations, their estimates are
similar to ours, but they were based on extrapolated birth cohort
survivor curves, while our estimates use current mortality rates
across all ages. MacKenzie and colleagues found that for a child
born and diagnosed with CF in the US in 2010 the estimated
median survival was 39 for males and 35 for females in the
F508del homozygous group [14]. Their estimates for homozy-
gotes are lower than ours, because they refer to 2010 whereas we
used data up to the end of 2015 and because survival estimates for
the US are lower than for the UK [1,22].
Our study provides survival information for individuals living
with CF who have already reached a given age, which has been
extremely limited to date. Conditional estimates of survival are
most relevant for patients and clinicians. Given survival to age 30
in F508del homozygotes, we found median survival age of 53 for
males and 49 for females, which are increases of seven and eight
years respectively compared to survival from birth. Estimated
conditional median survival ages were found to be considerably
higher for non-F508del homozygotes diagnosed at an older age.
Dodge and colleagues presented conditional life expectancies (a
mean rather than a median) for a series of ages up to age 30 for
males and females separately [4]. The expectation of life in males
and females who had reached age 30 in 2003 were 52 and
49 years respectively. Nick et al. presented median survival
estimates for long term survivors (to age 40 plus) of CF in the US
stratified by sex and age of diagnosis, finding estimated median
survival ages from age 40 of 54 for those diagnosed in childhood
(age ≤10) and 68 for those diagnosed in adulthood (age ≥18)
[23]. These earlier estimates did not take into account genotype.
We have also produced projections of future survival in CF in
the UK under two further scenarios. These estimates are most
appropriate for the families of babies being born in the present day
with CF, and can be used to inform future needs in CF health care
provision. MacKenzie and colleagues estimated a decrease in
mortality rates of 1.8% per calendar year using US Registry data
from 2000 to 2010 [14], which is very similar to our estimate of
2% for the UK. Continued improvements at this rate in the future
correspond to an increase in median survival age of 20 years in
males and 15 years in females compared to estimates that do not
take into account the secular downward trend in mortality. These
increases are similar to those found byMacKenzie and colleagues,
though their actual estimates were lower [14].
The baseline characteristics of sex, F508del status and age at
diagnosis were incorporated into our survival estimates. Sex was
associated with survival independently of the other two character-
istics, and age at diagnosis was an important predictor of survival in
non-F508del homozygotes but not in homozygotes. MacKenzie
and colleagues found sex, F508del status and age at diagnosis to be
independently associated with survival in the US setting, but did
not investigate an interaction between genotype and age at
diagnosis [14]. Such an interaction could be country-specific due
to differing health care systems. Females have long been found to
have worse survival in CF compared to males and our findings
further support that phenomenon in up-to-date data [24]. More
research using longitudinal data is needed to elucidate the
pathways to worse outcome for females [25–27]. Older age at
diagnosis has also previously been associated with better prognosis
[23]. Sensitivity analyses restricting to individuals aged under 18 at
diagnosis did not materially impact on the results. It is likely that
the impact of age at diagnosis in the non-F508del homozygotes at
least in part represents the impact of milder genotypes on the
second (or both) allele [23]. We considered using genotype risk
class (I, II, III, IV, V, or groupings thereof) [28] in place of F508del
status. However, genotype risk class was missing in 15% of
individuals (due to missing information one or both mutations, or
due to an unclassified mutation) and the missingness was strongly
suspected to be missing not at random. In the primary data set only
six deaths were observed for individuals in classes III–V, which
was insufficient to allow sensible analysis. In further investigations
using the main study sample we found that in non-F508del
homozygotes, 57% of those diagnosed under age five had a high
risk genotype (where genotype risk class was observed), according
to the genotype classification of McKone and colleagues [28],
compared with only 14% of those diagnosed after age five. Further
work into survival for specific sub-categories of non-F508del
homozygotes would be of interest. Our genotype categorization
has the advantage of being understandable for patients, based on
sufficiently large numbers to obtain precise estimates, and
observed for nearly all patients.
Significant strengths of the data used in this study include that
there is very little loss-to-follow-up or missing data on the
variables considered. Although there were some missing data on
genotype and age at diagnosis, the amount of missingness was so
small that it is unlikely to have had significant impact on results.
Our study also has some limitations. Survival data for younger
ages are based on individuals born in the era of newborn
screening for CF, introduced in the UK in 2007 [15,29], while
survival data for older individuals includes a greater proportion
diagnosed at an older age. Accordingly, survival data from people
of older ages are necessarily based on individuals born in older
birth cohorts who have not received the same care and treatments
at younger ages as more recent birth cohorts. The survival curves
therefore cannot fully reflect current standards of care. Reducing
deaths in the childhood period is an important goal of CF care,
and in our analysis 8% of deaths (N = 49) were in CF patients
under the age of 18 years. Additionally, our projections do not
account for emerging therapies aimed at correcting the underlying
defect of CFTR [6,7], whichmay have differential impact in some
groups of individuals; however, the more realistic scenarios and
projections reported here offer insights into potential survivorship
gains. Age at diagnosis was found to be an important predictor of
survival in non-homozygotes, but we could not present projected
survivor curves for non-homozygotes born at an older age
because we did not have data on survival from birth in those types
of individuals. The conditional estimates are, however, still
relevant for individuals living with CF who were born in the
pre-newborn screening era. Although we found that age at
diagnosis was not an important factor in survival for F508del
homozygotes, the availability of newborn screening is still likely
to have impacted on survival for this group via improved
treatment at younger ages [30].
In summary, we have used data from the UK CF Registry,
which has almost complete coverage of the national CF
population, to provide up-to-date and precisely estimated survival
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curves that can be used by clinicians to effectively convey
information on mortality to patients and families. Our study
applies state of the art statistical methodology using flexible
parametric survival curves, enabling incorporation of baseline
characteristics and extrapolation to make future predictions, while
providing an excellent fit to the data. Babies born with CF in the
UK today can reasonably expect to live beyond their 50th
birthday, as can individuals living with CF today who have
already reached age 30 or older.
It is important that patients and care-givers are supported to
interpret survival estimates, the uncertainty around those esti-
mates, and the caveats to them. Indeed, there is much scope for
further qualitative work with patients and clinicians to better
understand how they make use of survival data in CF, drawing on
insights from the risk communication literature [31,32].
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